Sight Sciences, Inc. (NASDAQ:SGHT) Insider Jeremy B. Hayden Sells 4,878 Shares

Sight Sciences, Inc. (NASDAQ:SGHT) insider Jeremy B. Hayden sold 4,878 shares of Sight Sciences stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $6.08, for a total transaction of $29,658.24. Following the transaction, the insider now directly owns 158,687 shares of the company’s stock, valued at $964,816.96. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Sight Sciences Stock Down 3.2 %

Sight Sciences stock opened at $5.81 on Friday. Sight Sciences, Inc. has a twelve month low of $1.04 and a twelve month high of $8.45. The company has a 50 day moving average of $6.46 and a 200-day moving average of $6.24. The stock has a market capitalization of $292.30 million, a PE ratio of -5.19 and a beta of 2.71. The company has a quick ratio of 10.50, a current ratio of 11.01 and a debt-to-equity ratio of 0.33.

Sight Sciences (NASDAQ:SGHT) last released its earnings results on Thursday, August 1st. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.06. Sight Sciences had a negative return on equity of 45.68% and a negative net margin of 65.90%. The business had revenue of $21.37 million for the quarter, compared to analyst estimates of $21.32 million. During the same quarter in the prior year, the company posted ($0.30) earnings per share. On average, equities research analysts anticipate that Sight Sciences, Inc. will post -1 EPS for the current fiscal year.

Hedge Funds Weigh In On Sight Sciences

Institutional investors have recently bought and sold shares of the business. Long Focus Capital Management LLC lifted its stake in shares of Sight Sciences by 86.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 560,594 shares of the company’s stock worth $3,739,000 after buying an additional 260,594 shares during the last quarter. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Sight Sciences in the second quarter valued at approximately $1,234,000. RTW Investments LP acquired a new stake in shares of Sight Sciences in the fourth quarter valued at approximately $850,000. Vanguard Group Inc. raised its position in shares of Sight Sciences by 5.5% in the first quarter. Vanguard Group Inc. now owns 1,556,450 shares of the company’s stock valued at $8,218,000 after buying an additional 81,768 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its position in shares of Sight Sciences by 25.5% in the first quarter. Jacobs Levy Equity Management Inc. now owns 377,057 shares of the company’s stock valued at $1,991,000 after buying an additional 76,549 shares in the last quarter. Institutional investors and hedge funds own 55.51% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on SGHT shares. Needham & Company LLC reiterated a “hold” rating on shares of Sight Sciences in a research report on Friday, August 2nd. Citigroup lifted their price target on shares of Sight Sciences from $6.00 to $6.50 and gave the stock a “neutral” rating in a research report on Wednesday, July 10th. Morgan Stanley lifted their price target on shares of Sight Sciences from $5.40 to $6.50 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Finally, Lake Street Capital assumed coverage on shares of Sight Sciences in a report on Wednesday, August 21st. They set a “buy” rating and a $10.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $7.25.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.